Overview
Legal name
PURIDIFY LTD.
Region
East of England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Puridify LTD.
Puridify LTD. is a UK company with status active founded in 2013 based in East of England.
CRN
08446072
Founded
2013
Age
12
Corporate ownership
Updated 06 Jun 2026 16:52
7 levels
1 ultimate controller
1
Company
Active
LTD
Puridify LTD.
CRN 08446072
2
Direct controller
Active
LTD
Launchchange Operations Limited
CRN 07105768
3
Intermediate controller
Active
LTD
Launchchange Limited
CRN 02639894
4
Intermediate controller
Active
LTD
Launchchange UK Holdco Limited
CRN 13738808
5
Intermediate controller
Active
LTD
Launchchange Instrumentation Limited
CRN 02330973
6
Intermediate controller
Active
PRIVATE-UNLIMITED
VR Finance Company
CRN 03428240
7
Intermediate controller
Active
PRIVATE-UNLIMITED
Launchchange Holding Company
CRN 03259276
8
Ultimate controller
02103594
CRN 02103594
Company events
Reference milestones and recent Companies House filing stream events.
2 events
29 Aug
2024
Change Account Reference Date Company Previous Extended
Accounts Awaiting analysisAA01 | Transaction MzQzMzc5MTIwN2FkaXF6a2N4
Published 29 Aug 2024 10:02
15 Mar
2013
Incorporated
InceptionCompany registered at Companies House
Public funding
6 awards
First funded
2013
Funded years
2013, 2014, 2015, 2016, 2018
Age at first award
0 years
Projects
2018
Feasibility Studies
Lead participant
Developing a marketable FibroSelect platform for bespoke viral vector purifications
1 Apr 2018 to 31 Mar 2019
Awarded
£193,881
Total cost £387,762
Gene therapy is an exciting new wave of medicine whereby therapeutic DNA is delivered into patients' cells to correct genetic disorders, use the body's own cells to make therapeutic proteins, or empower one's immune system to better fight cancer. Development of these advanced therapies is however still at a relatively early stage and current manufacturing...
2016
Collaborative R&D
Lead participant
Development and optimisation of downstream processing for next generation biotherapeutics
1 Jan 2016 to 30 Sep 2017
Awarded
£975,722
Total cost £1,393,888
Global demand for cheaper biotherapeutics drives the need for a reduction in manufacturing costs. Rapid advances in recombinant production technologies are offering new therapeutic possibilities in the treatment of illnesses such as haemophilia, Parkinson’s, and cancer. However, purification of these next generation protein therapeutics is extremely chall...
2015
Collaborative R&D
Industrial validation of nanofibre platform technology for biotherapeutics manufacture
1 Apr 2015 to 31 Mar 2017
Awarded
£1,044,890
Total cost £1,741,484
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies used to ensure the safety and efficacy of these treatments...
2014
Collaborative R&D
Lead participant
Novel purification technologies for industrial biotherapeutic manufacture
1 May 2014 to 31 Oct 2015
Awarded
£214,264
Total cost £357,107
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these...
2014
Feasibility Studies
Lead participant
High-flowrate nanofibre biocatlysis
1 Feb 2014 to 31 Oct 2014
Awarded
£65,654
Total cost £87,539
This project seeks to apply a novel nanofibre material to industrial biocatalysis for the first time. The goal being to reduce the costs and environmental impact compared to traditional chemical synthesis. The results of the project will be a global product delivering revenues to two UK based companies who will re-invest the proceeds in research and devel...
2013
GRD Proof of Concept
Lead participant
High Productivity Downstream Purifications
1 Oct 2013 to 30 Jun 2014
Awarded
£100,000
Total cost £167,313
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these...
Product types
Collaborative R&D
Feasibility Studies
GRD Proof of Concept